BAMLANIVIMAB

Course overview

BAMLANIVIMAB IS AN INVESTIGATIONAL DRUG DEVELOPED FOR COVID-19 PNEUMONIA. IT IS IN THE CLASS OF NEUTRALIZING MONOCLONAL ANTIBODIES. THIS ACTIVITY ILLUSTRATES THE INDICATIONS, ACTION, AND CONTRAINDICATIONS FOR BAMLANIVIMAB AS A NOVEL AGENT IN THE TREATMENT AND POST-EXPOSURE PROPHYLAXIS OF COVID 19. THIS ACTIVITY WILL HIGHLIGHT THE MECHANISM OF ACTION, ADVERSE EVENTS, MONITORING, AND RELEVANT INTERACTIONS PERTINENT TO THE HEALTHCARE TEAM IN MANAGING PATIENTS WITH COVID-19, ESPECIALLY IN AN AMBULATORY SETTING.